APG
DNA icon

Abacus Planning Group’s Ginkgo Bioworks DNA Stock Holding History

Abacus Planning Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-603
Closed -$8.06K – 219
2024
Q2 		$8.06K Hold
603
– – ﹤0.01% 218
2024
Q1 		$28K Hold
603
– – 0.01% 206
2023
Q4 		$40.8K Hold
603
– – 0.01% 199
2023
Q3 		$43.6K Hold
603
– – 0.01% 187
2023
Q2 		$44.9K Hold
603
– – 0.01% 196
2023
Q1 		$32.1K Hold
603
– – 0.01% 190
2022
Q4 		$40.8K Hold
603
– – 0.01% 178
2022
Q3 		$75K Hold
603
– – 0.02% 168
2022
Q2 		$57K Hold
603
– – 0.02% 187
2022
Q1 		$97K Buy
603
+224
+59% +$43.6K 0.03% 197
2021
Q4 		$126K Hold
379
– – 0.03% 203
2021
Q3 		$176K Buy
+379
New +$184K 0.06% 178

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Abacus Planning Group's DNA Position: Q3 2024 in Review

Abacus Planning Group sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 603 shares — an estimated $8.06K sold.

Abacus Planning Group first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $176K in Q3 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Abacus Planning Group reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Abacus Planning Group sold 603 Ginkgo Bioworks shares in Q3 2024, an estimated $8.06K.
  • Abacus Planning Group first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Abacus Planning Group's Ginkgo Bioworks position peaked at $176K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Abacus Planning Group's 13F filing for Q3 2024, filed 2 Oct 2024.